logo

Cara Therapeutics Inc. (CARA)



Trade CARA now with
  Date
  Headline
7/19/2018 8:12:40 AM Cara Therapeutics Doses First Patient In Phase 2 Trial Of Peptelligence-Engineered Oral KORSUVA
7/18/2018 9:05:18 PM Cara Therapeutics Announces Pricing Of Its Underwritten Public Offering Of 4.50 Mln Shares At $19.00/shr
7/17/2018 4:24:11 PM Cara Therapeutics Begins Public Offering Of 4.50 Mln Shares Of Its Common Stock
7/11/2018 7:04:01 AM Cara Therapeutics Says First Patients Dosed In Phase 2 Trial Of Oral KORSUVA
6/27/2018 7:16:30 AM Cara Therapeutics, Trading Expected To Resume At 7:30 AM ET
6/27/2018 7:03:49 AM Cara Therapeutics Reports Positive Top-Line Data From Adaptive Phase 2/3 Trial Of I.V. CR845
6/27/2018 6:57:43 AM Cara Therapeutics, Trading Halt Pending News
2/28/2018 7:07:56 AM Cara Therapeutics Doses First Patient In Phase 1 Safety And Pharmacokinetic Trial Of Oral KORSUVA
1/31/2018 7:10:52 AM Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of KORSUVA Injection